Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 5;13(5):585-599.
doi: 10.4103/idoj.idoj_189_22. eCollection 2022 Sep-Oct.

Role of Cyclosporine (CsA) in Immuno-dermatological Conditions

Murlidhar Rajagopalan  1 , Abir Saraswat  2 , Byalakere Shivanna Chandrashekar  3 , Sandipan Dhar  4 , Sunil Dogra  5 , Sushil Tahiliani  6 , Praveen Raj  7
Affiliations

Role of Cyclosporine (CsA) in Immuno-dermatological Conditions

Murlidhar Rajagopalan et al. Indian Dermatol Online J. .

Abstract

Cyclosporine (CsA) is a calcineurin inhibitor that acts selectively on T cells. It has been used in dermatology since 1997 for its US Food and Drug Administration indication of psoriasis and off-label for various other inflammatory skin conditions, including atopic dermatitis, alopecia areata, urticaria, lichen planus and many others in pediatric, adults as well as in pregnant women. However, clinicians' preferences for management differ, which may have a bearing on the treatment selection. Hence, the purpose of this review is to outline the role of CsA in various skin conditions through consensus statement from six national experts in the field of dermatology.

Keywords: Alopecia areata; Cyclosporine (CsA); lichen planus; psoriasis; vitiligo.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Ferns G, Reidy M, Ross R. Vascular effects of cyclosporine A in vivo and in vitro. Am J Pathol. 1990;137:403. - PMC - PubMed
    1. Lim KK, Daniel WP, Schroeter AL, Sabers CJ, Abraham RT, Pittelkow MR. Cyclosporine in the treatment of dermatologic disease:An update. Mayo Clin Proc. 1996;71:1182–91. - PubMed
    1. Elliott JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkau V. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science. 1984;226:1439–41. - PubMed
    1. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645–53. - PMC - PubMed
    1. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90:232. - PMC - PubMed